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A Great Start, But the Promise
of Biodegradable Stents
Remains to Be Proven*Barry T. Katzen, MD
Miami, Florida
In this issue of JACC: Cardiovascular Interventions, Werner
et al. (1) present their experience with the use of
a biodegradable balloon expandable stent for use in the
superﬁcial femoral artery (SFA). This stent, which is com-
mercially available outside the United States, is composed
of poly-L-lactic acid (PLLA) and undergoes degradation in
the human body through a process of hydrolysis over a long
period of time. In this particular device, structural integrity
is maintained for 6 months, following which, degradation
begins and can last up to 3 years, at which point no more
material is detectable.See page 305The concept of biodegradable stents is a good one, if
clinical beneﬁts equal to the current standard of care in
the SFA, self-expandable nitinol stents, can be obtained.
Although a “stenting ﬁrst” strategy for treating SFA lesions
has been demonstrated to be beneﬁcial (2,3), the superﬁcial
femoral artery has proven quite hostile to metallic devices,
resulting in stent fractures in some cases (4). Restenosis
remains a fundamental challenge, but outcomes have been
steadily improving as stents designed speciﬁcally for this
anatomy have been developed and tested in clinical trials (5).
The study is relatively small at 30 patients, but it is pro-
spective and multicenter, and importantly has nearly com-
plete intermediate-term follow-up to 12 months. The device
is delivered over a 0.018-inch guidewire, with balloon ex-
pansion, and post-stenting, additional dilation if residual
stenosis was noted. A relatively large 7-F sheath is required
for delivery. The technical success was extremely high, but
not 100% because of a balloon failure, managed with
removal of the failed device and use of an additional device.*Editorials published in JACC: Cardiovascular Interventions reﬂect the views of the
authors and do not necessarily represent the views of JACC: Cardiovascular
Interventions or the American College of Cardiology.
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holds the Endowed Chair of Cook Medical.Admirably, all patients received the study stent. An mean
lesion length of 5.9 cm is in line with recent bare-metal
stent studies, Anticoagulation consisted of heparin during
the procedure, followed by dual antiplatelet therapy (aspirin
and clopidogrel) for 6 months. The trial was conducted
well, providing good data for analysis of the ﬁrst clinical
experience of this device in the SFA.
The authors have demonstrated that excellent short-
term results can be achieved using this PLLA stent. This
was conﬁrmed with a short-term technical success rate of
96.7%, but all patients received a biodegradable stent. One
concern with biodegradable materials is in the structural
support to provide scaffolding of the plaque-laden SFA. The
short-term results with mean residual stenosis of 6.2%
conﬁrms that use of this device achieved a desirable short-
term procedural result.
The other important unknowns regarding this type of
device are the ability to provide sustainable luminal patency
over time through mechanical support and the ability of
the stent to reduce restenosis, and to provide patency su-
perior to angioplasty alone. Restenosis rates at 9 and 12
months of 60.7% and 67.9%, respectively, are of concern
and are associated with a primary patency rate of 32.1% at
12 months, more or less equivalent to angioplasty. Although
the restenosis rates were deﬁned and not always clinically
driven, they do raise concern about durability and healing
long term. Secondary patency was achieved in a high percent
of patients, 89.3%, with 2 total occlusions that were
managed with lysis, and importantly, 16 of the 30 patients
underwent secondary intervention.
There is great enthusiasm for biodegradable devices, but
this study raises concerns about this device being able to
result in sustainable results. The authors speculate about the
role of thrombus in the restenosis process with this stent,
and this certainly requires further study and might be
manageable with directed medical therapy. However, more
likely, pharmacological mediation may require addition of
drug therapy within the stent itself to provide long-term
beneﬁts. This study tempers the promise of biodegradable
devices with the reality of outcomes in the challenging
anatomy of the SFA. Although the device is able to achieve
satisfactory short-term outcomes, further study and modi-
ﬁcation will be required to improve outcomes to the ex-
pected levels of contemporary self-expanding nitinol stents.
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